SCHEMBL6877310

SCHEMBL6877310

CON(Cc1ccc(F)c(Cl)c1)C(=O)/C=C(\O)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPA1 P27694 1/20 0.38
PIK3CA P42336 1/20 0.36
SLC6A9 P48067 2/20 0.35
KCNH2 Q12809 2/20 0.35
KDM5A P29375 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
CNR2 P34972 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GRM2 Q14416 1/20 0.34
GRM3 Q14832 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 2/20 0.34
NPC1 O15118 2/20 0.34
MAPT P10636 2/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MITF O75030 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6877313 1.00 RPA1 (0.38) RPA1PIK3CASLC6A9KCNH2KDM5A
SCHEMBL6077790 0.91 RPA1 (0.36) RPA1PIK3CASLC6A9KCNH2KDM4E
SCHEMBL6077788 0.91 RPA1 (0.36) RPA1PIK3CASLC6A9KCNH2KDM4E
SCHEMBL6880571 0.89 TSHR (0.43) TSHRMAPTSMN1; SMN2MAOAMAOB
SCHEMBL6880573 0.89 TSHR (0.43) TSHRMAPTSMN1; SMN2MAOAMAOB
SCHEMBL6879340 0.89 RIPK1 (0.41) KDM5AKDM5BKDM4EALDH1A1L3MBTL1
SCHEMBL6871727 0.89 RIPK1 (0.41) KDM5AKDM5BKDM4EALDH1A1L3MBTL1
SCHEMBL6865927 0.86 MMP13 (0.36) KDM4EALDH1A1L3MBTL1GRM2GRM3
SCHEMBL6865928 0.86 MMP13 (0.36) KDM4EALDH1A1L3MBTL1GRM2GRM3
SCHEMBL6879324 0.85 NPSR1 (0.41) KDM4EALDH1A1L3MBTL1TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1467695-A2 HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2004-10-20 EP disclosed
US-6777440-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-08-17 US disclosed
US-20030176495-A1 HIV Integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-09-18 US disclosed
WO-2003049690-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176495-A1 HIV Integrase inhibitors MAPT, RIF1, HPRT1 RPA1 107/4885PIK3CA 347/4885SLC6A9 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.